Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
GANTANOL-DS is an oral tablet antibiotic approved in 1965 by Roche, containing sulfamethoxazole as the active ingredient. The drug is a sulfonamide antibiotic used to treat bacterial infections across multiple therapeutic areas. It represents a legacy small-molecule product with a well-established safety and efficacy profile spanning nearly 60 years of clinical use.
With LOE approaching and moderate competitive pressure (30), expect significant portfolio contraction and team reductions; limited growth opportunities for new hires.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on GANTANOL-DS offers limited career growth; roles are typically focused on cost management, regulatory compliance, and managed decline rather than business expansion. This is a suitable assignment for career stabilization or operational expertise development, but not for advancement into high-visibility brand leadership.
Worked on GANTANOL-DS at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.